TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.

Kaufmann, S., Dockrell, H., Drager, N., Mei Mei, H., Mcshane, H., Neyrolles, O., et al. (2017). TBVAC2020: Advancing tuberculosis vaccines from discovery to clinical development. FRONTIERS IN IMMUNOLOGY, 8(OCT), 1-18 [10.3389/fimmu.2017.01203].

TBVAC2020: Advancing tuberculosis vaccines from discovery to clinical development

Romano, Marta;Caccamo, Nadia;Goletti, Delia;
2017-01-01

Abstract

TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.
https://www.frontiersin.org/articles/10.3389/fimmu.2017.01203/full
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632681/
Kaufmann, S., Dockrell, H., Drager, N., Mei Mei, H., Mcshane, H., Neyrolles, O., et al. (2017). TBVAC2020: Advancing tuberculosis vaccines from discovery to clinical development. FRONTIERS IN IMMUNOLOGY, 8(OCT), 1-18 [10.3389/fimmu.2017.01203].
File in questo prodotto:
File Dimensione Formato  
Kaufmann 2017.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 1.33 MB
Formato Adobe PDF
1.33 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/252195
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 32
social impact